U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C40H59NO11
Molecular Weight 729.8981
Optical Activity UNSPECIFIED
Defined Stereocenters 19 / 19
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERIBULIN

SMILES

C[C@]1([H])C[C@]2([H])CC[C@@]3([H])C(=C)C[C@]([H])(CC[C@@]45C[C@]6([H])[C@@]([H])([C@@]7([H])[C@]([H])([C@]([H])([C@]8([H])[C@]([H])(CC[C@]([H])(CC(=O)C[C@@]9([H])[C@]([H])(C[C@]([H])(C1=C)O2)O[C@]([H])(C[C@@]([H])(CN)O)[C@]9([H])OC)O8)O7)O4)O6)O5)O3

InChI

InChIKey=UFNVPOGXISZXJD-JBQZKEIOSA-N
InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1

HIDE SMILES / InChI
ERIBULIN MESYLATE (HALAVEN®) is a microtubule dynamics inhibitor. It is a synthetic analog of halichondrin B, a product isolated from the marine sponge Halichondria okadai. ERIBULIN MESYLATE (HALAVEN®) inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. It exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after the prolonged mitotic blockage. ERIBULIN MESYLATE (HALAVEN®) is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. It is also indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9H4B7
Gene ID: 81027.0
Gene Symbol: TUBB1
Target Organism: Homo sapiens (Human)
1.4 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HALAVEN

Approved Use

HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (1.1) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (1.2) 1.1 Me tastatic Breast Cancer HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies (14.1)

Launch Date

1.28977915E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1213.3 ng/mL
1.5 mg/m² 2 times / 4 weeks multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ERIBULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32364.4 ng × h/mL
1.5 mg/m² 2 times / 4 weeks multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ERIBULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
28.07 h
1.5 mg/m² 2 times / 4 weeks multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ERIBULIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
43%
ERIBULIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources: Page: p. 125
unhealthy, 55 years (range: 28 - 85 years)
n = 508
Health Status: unhealthy
Age Group: 55 years (range: 28 - 85 years)
Sex: M+F
Population Size: 508
Sources: Page: p. 125
Disc. AE: Neurotoxicity, Elevated liver enzymes...
AEs leading to
discontinuation/dose reduction:
Neurotoxicity (6%)
Elevated liver enzymes (1%)
Sources: Page: p. 125
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
DLT: Fatigue, Anorexia...
Other AEs: Vomiting, Nausea...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Anorexia (grade 3, 1 patient)
Other AEs:
Vomiting (grade 3, 11%)
Nausea (grade 1-2, 44%)
Neutropenia (grade 1-2, 22%)
Diarrhea (grade 1-2, 44%)
Anemia (grade 1-2, 11%)
Alopecia (grade 1-2, 11%)
Stomatitis (grade 1-2, 22%)
Sources:
0.5 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 0.5 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 0.5 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 8
Sources:
DLT: Fatigue...
Dose limiting toxicities:
Fatigue (grade 3, 1 patient)
Sources:
1.4 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1.4 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1.4 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
DLT: Neutropenia, Fatigue...
Dose limiting toxicities:
Neutropenia (grade 3-4, 2 patients)
Fatigue (grade 3, 1 patient)
Sources:
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources:
unhealthy, 58 years (range: 26 to 91 years)
n = 503
Health Status: unhealthy
Condition: multiple tumors
Age Group: 58 years (range: 26 to 91 years)
Sex: M+F
Population Size: 503
Sources:
Disc. AE: Peripheral neuropathy, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Peripheral neuropathy (1%)
Neutropenia (12%)
Sources:
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
DLT: Febrile neutropenia, Oral candidiasis...
Other AEs: Neutropenia, Leukopenia...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 1 patient)
Oral candidiasis (grade 2, 1 patient)
Other AEs:
Neutropenia (grade 3-4, 57%)
Leukopenia (grade 1-2, 14%)
Constipation (grade 1-2, 14%)
Dry mouth (grade 1-2, 14%)
Anorexia (grade 1-2, 29%)
Fatigue (grade 1-2, 29%)
Pyrexia (grade 1-2, 14%)
Cough (grade 1-2, 14%)
Alopecia (grade 1-2, 43%)
Pruritic rash (grade 1-2, 14%)
Sources:
2.8 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 2.8 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 3
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 3
Sources:
DLT: Febrile neutropenia...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 2 patients)
Sources:
4 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 4
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 4
Sources:
DLT: Febrile neutropenia...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 3 patients)
Sources:
5.6 mg/m2 2 times / 3 weeks multiple, intravenous
Overdose
Dose: 5.6 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 5.6 mg/m2, 2 times / 3 weeks
Sources:
unhealthy
Other AEs: Neutropenia, Hypersensitivity...
Other AEs:
Neutropenia (grade 3)
Hypersensitivity (grade 3)
Sources:
AEs

AEs

AESignificanceDosePopulation
Elevated liver enzymes 1%
Disc. AE
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources: Page: p. 125
unhealthy, 55 years (range: 28 - 85 years)
n = 508
Health Status: unhealthy
Age Group: 55 years (range: 28 - 85 years)
Sex: M+F
Population Size: 508
Sources: Page: p. 125
Neurotoxicity 6%
Disc. AE
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources: Page: p. 125
unhealthy, 55 years (range: 28 - 85 years)
n = 508
Health Status: unhealthy
Age Group: 55 years (range: 28 - 85 years)
Sex: M+F
Population Size: 508
Sources: Page: p. 125
Alopecia grade 1-2, 11%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Anemia grade 1-2, 11%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Neutropenia grade 1-2, 22%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Stomatitis grade 1-2, 22%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Diarrhea grade 1-2, 44%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Nausea grade 1-2, 44%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Anorexia grade 3, 1 patient
DLT
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Fatigue grade 3, 1 patient
DLT
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Vomiting grade 3, 11%
1 mg/m2 3 times / 3 weeks multiple, intravenous
MTD
Dose: 1 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Fatigue grade 3, 1 patient
DLT
0.5 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 0.5 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 0.5 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 8
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 8
Sources:
Fatigue grade 3, 1 patient
DLT
1.4 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1.4 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1.4 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Neutropenia grade 3-4, 2 patients
DLT
1.4 mg/m2 3 times / 3 weeks multiple, intravenous
Dose: 1.4 mg/m2, 3 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 1.4 mg/m2, 3 times / 3 weeks
Sources:
unhealthy, 57.4 years
n = 9
Health Status: unhealthy
Condition: Advanced Solid Malignancies
Age Group: 57.4 years
Sex: M+F
Population Size: 9
Sources:
Peripheral neuropathy 1%
Disc. AE
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources:
unhealthy, 58 years (range: 26 to 91 years)
n = 503
Health Status: unhealthy
Condition: multiple tumors
Age Group: 58 years (range: 26 to 91 years)
Sex: M+F
Population Size: 503
Sources:
Neutropenia 12%
Disc. AE
1.4 mg/m2 2 times / 3 weeks steady, intravenous
Recommended
Dose: 1.4 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: steady
Dose: 1.4 mg/m2, 2 times / 3 weeks
Sources:
unhealthy, 58 years (range: 26 to 91 years)
n = 503
Health Status: unhealthy
Condition: multiple tumors
Age Group: 58 years (range: 26 to 91 years)
Sex: M+F
Population Size: 503
Sources:
Constipation grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Cough grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Dry mouth grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Leukopenia grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Pruritic rash grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Pyrexia grade 1-2, 14%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Anorexia grade 1-2, 29%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Fatigue grade 1-2, 29%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Alopecia grade 1-2, 43%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Oral candidiasis grade 2, 1 patient
DLT
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Neutropenia grade 3-4, 57%
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Febrile neutropenia grade 4, 1 patient
DLT
2 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 7
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 7
Sources:
Febrile neutropenia grade 4, 2 patients
DLT
2.8 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 2.8 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 3
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 3
Sources:
Febrile neutropenia grade 4, 3 patients
DLT, Disc. AE
4 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 4 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 4 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 62 yeras (range: 29-73 years)
n = 4
Health Status: unhealthy
Condition: advanced solid tumors
Age Group: 62 yeras (range: 29-73 years)
Sex: M+F
Population Size: 4
Sources:
Hypersensitivity grade 3
5.6 mg/m2 2 times / 3 weeks multiple, intravenous
Overdose
Dose: 5.6 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 5.6 mg/m2, 2 times / 3 weeks
Sources:
unhealthy
Neutropenia grade 3
5.6 mg/m2 2 times / 3 weeks multiple, intravenous
Overdose
Dose: 5.6 mg/m2, 2 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 5.6 mg/m2, 2 times / 3 weeks
Sources:
unhealthy
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
weak [IC50 >10 uM]
yes [Ki 3 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

Administer HALAVEN® 1.4 mg/m2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Route of Administration: Intravenous
Name Type Language
ERIBULIN
INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
ERIBULIN [VANDF]
Common Name English
ER-086526
Code English
ERIBULIN [INN]
Common Name English
ERIBULIN [WHO-DD]
Common Name English
ERIBULIN [MI]
Common Name English
ERIBULIN [MART.]
Common Name English
Classification Tree Code System Code
LIVERTOX 364
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
NDF-RT N0000175592
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
NCI_THESAURUS C67422
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
WHO-ATC L01XX41
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
WHO-VATC QL01XX41
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
EMA ASSESSMENT REPORTS HALAVEN (AUTHORIZED: BREAST NEOLPLASMA)
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
Code System Code Type Description
WIKIPEDIA
ERIBULIN
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
IUPHAR
6813
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
PUBCHEM
11354606
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
RXCUI
1045453
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY RxNorm
FDA UNII
LR24G6354G
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1683590
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
INN
8854
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
CAS
253128-41-5
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
EVMPD
SUB31134
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
MESH
C490954
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
MERCK INDEX
M4993
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C96748
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
DRUG BANK
DB08871
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY
DRUG CENTRAL
4171
Created by admin on Sat Jun 26 02:32:39 UTC 2021 , Edited by admin on Sat Jun 26 02:32:39 UTC 2021
PRIMARY